Caplin Point Laboratories Ltd
NSE:CAPLIPOINT

Watchlist Manager
Caplin Point Laboratories Ltd Logo
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Watchlist
Price: 2 500.65 INR -1.48% Market Closed
Market Cap: 190.1B INR
Have any thoughts about
Caplin Point Laboratories Ltd?
Write Note

Caplin Point Laboratories Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Caplin Point Laboratories Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Depreciation & Amortization
-â‚ą630.2m
CAGR 3-Years
-14%
CAGR 5-Years
-18%
CAGR 10-Years
-29%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Depreciation & Amortization
-â‚ą15.2B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Depreciation & Amortization
-â‚ą10.4B
CAGR 3-Years
0%
CAGR 5-Years
5%
CAGR 10-Years
-9%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Depreciation & Amortization
-â‚ą25.5B
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
-14%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Depreciation & Amortization
-â‚ą8.1B
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
-21%
M
Mankind Pharma Ltd
NSE:MANKIND
Depreciation & Amortization
-â‚ą4B
CAGR 3-Years
-50%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Caplin Point Laboratories Ltd
Glance View

Market Cap
190B INR
Industry
Pharmaceuticals

Nestled in the bustling business corridors of Chennai, Caplin Point Laboratories Ltd. emerged quietly yet resolutely from its humble origins in 1990. With foresight and strategic maneuvering, the company embarked on a global journey, primarily serving markets across the African, Latin American, and Southeast Asian regions. The firm specializes in a wide array of pharmaceutical products, encompassing everything from injectables and ophthalmics to oral solids and liquids. By focusing on markets that were often overlooked by larger pharmaceutical giants, Caplin Point carved out a niche that allowed it to flourish with minimal competition. The company's business model hinges on leveraging cost-effective manufacturing paired with a deep understanding of diverse regulatory environments, deftly navigating these to establish a loyal customer base amidst underrepresented geographies. The revenue streams of Caplin Point Laboratories are primarily fueled by its ability to adapt product lines to meet the specific needs of each market it serves. This adaptability, combined with a robust distribution network, facilitates the swift movement of goods—ensuring prompt delivery to consumers who rely on its products for basic health needs. Through strategic partnerships and continual investment in research and development, Caplin Point enhances its capacity for innovation, allowing it to advance the quality and range of its pharmaceutical offerings. Furthermore, the company has steadily expanded into regulated markets with its sights set on injectables and has plans for further diversification. This strategic orientation underscores its ambition to transition from a regional powerhouse to a formidable player on the broader global stage.

CAPLIPOINT Intrinsic Value
1 180.05 INR
Overvaluation 53%
Intrinsic Value
Price

See Also

What is Caplin Point Laboratories Ltd's Depreciation & Amortization?
Depreciation & Amortization
-630.2m INR

Based on the financial report for Sep 30, 2024, Caplin Point Laboratories Ltd's Depreciation & Amortization amounts to -630.2m INR.

What is Caplin Point Laboratories Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-29%

Over the last year, the Depreciation & Amortization growth was -38%. The average annual Depreciation & Amortization growth rates for Caplin Point Laboratories Ltd have been -14% over the past three years , -18% over the past five years , and -29% over the past ten years .

Back to Top